Research guide · Published July 22, 2026 · Sources checked July 22, 2026
FOXO4-DRI, p53, and cellular senescence: an evidence guide
FOXO4-DRI is a D-retro-inverso peptide designed to interfere with an interaction between the FOXO4 transcription factor and p53 in selected senescent-cell models. The name refers to FOXO4, or forkhead box O4—not a compound numbered ‘FOX-04.’
Short answer
The foundational hypothesis is that disrupting a FOXO4–p53 interaction can promote p53 redistribution and apoptosis in selected senescent cells. Later studies examined additional cell types and mouse models. This remains model-dependent preclinical research and does not establish a general anti-aging or longevity effect in humans.
Evidence boundary: The cited studies do not establish clinical safety, human longevity, broad rejuvenation, or effectiveness across all senescent-cell types. Catalog materials are supplied only for qualified in vitro laboratory research and are not for human or animal use.
Comparison at a glance
| Evidence layer | Material and model | Key interpretation limit |
|---|---|---|
| Foundational study | FOXO4-DRI in senescent human fibroblast systems and aged or progeroid mice | One study does not establish universal senescent-cell selectivity |
| Keloid research | Senescence-associated keloid organ cultures and fibroblasts | A specialized scar model is not general aging evidence |
| Vascular-aging research | OGD-associated endothelial-cell models and naturally aged or progeroid mice | Cell and mouse vascular endpoints are not clinical outcomes |
| Molecular interpretation | FOXO4–p53 interaction, phosphorylated-p53 localization, and apoptosis-associated measurements | Pathway measurements do not verify a separately manufactured peptide batch |
How to interpret the comparison
Cellular senescence is heterogeneous: triggers, tissues, markers, and survival pathways differ. A material that changes one senescent-cell model should not automatically be labeled a universal senolytic.
D-retro-inverso design changes residue chirality and sequence orientation to preserve selected side-chain topology while altering peptide properties. Exact sequence, stereochemistry, analytical identity, and the study material therefore matter when matching literature to a supplied batch.
Primary sources
- Baar et al., Cell (2017) — Foundational cell and mouse study targeting the FOXO4–p53 interaction in selected senescence models. DOI: 10.1016/j.cell.2017.02.031
- Kong et al., Communications Biology (2025) — Keloid organ-culture and fibroblast research examining p53-serine-15 phosphorylation and FOXO4-DRI-associated apoptosis. DOI: 10.1038/s42003-025-07738-0
- Hu et al., Frontiers in Bioengineering and Biotechnology (2026) — Endothelial-cell and mouse vascular-aging models focused on FOXO4–p53 signaling and apoptosis-associated measurements. DOI: 10.3389/fbioe.2025.1729166
Continue in the research library
Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.